These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9248959)

  • 21. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
    Linares MJ; Charriel G; Solís F; Casal M
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media].
    Tapia C; León E; Palavecino E
    Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
    Morace G; Polonelli L;
    Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro susceptibility testing in fungi: a global perspective on a variety of methods.
    Lass-Flörl C; Perkhofer S; Mayr A
    Mycoses; 2010 Jan; 53(1):1-11. PubMed ID: 20078786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance.
    Espinel-Ingroff A; Warnock DW; Vazquez JA; Arthington-Skaggs BA
    Med Mycol; 2000; 38 Suppl 1():293-304. PubMed ID: 11204157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AIDS‐associated Cryptococcus neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resource‐limited settings.
    Le T; Hong Chau TT; Kim Cuc NT; Si Lam P; Manh Sieu TP; Shikuma CM; Day JN
    Clin Infect Dis; 2010 Nov; 51(9):e65-8. PubMed ID: 20887205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifungal susceptibility testing: technical advances and potential clinical applications.
    Pfaller MA; Rex JH; Rinaldi MG
    Clin Infect Dis; 1997 May; 24(5):776-84. PubMed ID: 9142769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem].
    Pittrow L; Penk A
    Mycoses; 1996; 39 Suppl 2():58-65. PubMed ID: 9198747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options.
    Klepser ME; Lewis RE; Pfaller MA
    Ann Pharmacother; 1998 Dec; 32(12):1353-61. PubMed ID: 9876818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro assessment of antifungal drug resistance.
    Holmberg K
    Acta Derm Venereol Suppl (Stockh); 1986; 121():131-8. PubMed ID: 3459340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antifungal susceptibility testing: practical aspects and current challenges.
    Rex JH; Pfaller MA; Walsh TJ; Chaturvedi V; Espinel-Ingroff A; Ghannoum MA; Gosey LL; Odds FC; Rinaldi MG; Sheehan DJ; Warnock DW
    Clin Microbiol Rev; 2001 Oct; 14(4):643-58, table of contents. PubMed ID: 11585779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standardization of antifungal susceptibility testing and clinical relevance.
    Espinel-Ingroff A; Barchiesi F; Hazen KC; Martinez-Suarez JV; Scalise G
    Med Mycol; 1998; 36 Suppl 1():68-78. PubMed ID: 9988494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug susceptibility in emerging fungal infections: tests with fluconazole, itraconazole, and amphotericin B.
    Fay VDS; Rodrigues DMG; Gonçalves SMB; Gregianini TS; Bonamigo RR
    An Bras Dermatol; 2018 Jun; 93(3):462-464. PubMed ID: 29924220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Importance of the new triazoles in antifungal therapy].
    Durmaz B
    Mikrobiyol Bul; 1991 Jan; 25(1):118-23. PubMed ID: 1652677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is antifungal susceptibility testing useful in guiding fluconazole therapy?
    Ghannoum MA
    Clin Infect Dis; 1996 May; 22 Suppl 2():S161-5. PubMed ID: 8722845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fungal susceptibility testing: where are we now?
    Patterson TF
    Transpl Infect Dis; 2002; 4 Suppl 3():38-45. PubMed ID: 12486791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current topics in mycology].
    Khan M; Plempel M; Wassilew SW
    Z Hautkr; 1989 Oct; 64(10):837-8, 841-2. PubMed ID: 2686240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of azoles in antifungal therapy.
    Kauffman CA
    Clin Infect Dis; 1996 May; 22 Suppl 2():S148-53. PubMed ID: 8722843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints.
    Pittrow L; Penk A
    Mycoses; 1997; 40(1-2):25-32. PubMed ID: 9260478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 12-year study of fungal infections in Rio Grande do Sul, Southern Brazil.
    Fay VDS; Gregianini TS; Veiga ABGD; Gonçalves SMB; Rodrigues DM; Bonamigo RR
    Rev Iberoam Micol; 2019; 36(2):55-60. PubMed ID: 31014946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.